Related Experiment Video

Updated: Jan 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Survival in Oligometastatic Prostate Cancer-A New Dawn or the Will Rogers Phenomenon?

Martin J Connor1, Mathias Winkler1,2, Hashim U Ahmed1,2

  • 1Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Charing Cross Hospital, Imperial College London, London, United Kingdom.

JAMA Oncology
|December 6, 2019
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.8K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.9K

Related Experiment Videos

Last Updated: Jan 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.8K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.9K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

610
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
610

Articles linked to this work by shared authors, journal, and citation graph.

The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer.

BJU international·2026

Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1-LaserComplete study).

BJU international·2026

Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries.

European urology·2026

Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.

European urology oncology·2026

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology·2026

Delphi consensus on ex vivo fluorescence confocal microscopy in robot-assisted radical prostatectomy.

BJU international·2026

Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer: A Review.

JAMA oncology·2026

Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma.

JAMA oncology·2026

Disparities in Cancer Incidence by Sex and Associated Lifestyle Factors and Health Conditions.

JAMA oncology·2026

Chemotherapy and Surgical Outcomes for Ovarian Metastases From Colorectal Cancer: A Narrative Review.

JAMA oncology·2026

Immunotherapy in Head and Neck Squamous Cell Carcinoma With PD-L1 Combined Positive Score Less Than 1: A Bayesian Meta-Analysis.

JAMA oncology·2026

PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

JAMA oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us